Gilead Sciences (GILD) call put ratio 1 call to 2.5 puts amid price movement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025'
March 19, 2025 10:08 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD)
The analyst comments "While recent reports (WSJ, Mar 18) suggest the Department of Health and Human Services may cut federal funding for HIV prevention, we believe... More
